Investigating how IL-6 blockade can improve melanoma treatment outcomes
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
This study is looking at how a protein called IL-6 affects melanoma patients who are being treated with immune therapies like nivolumab, to find out if it can help predict how well the treatment will work and improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10881742 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of IL-6 and its associated proteins in melanoma patients treated with immune checkpoint inhibitors like nivolumab. By analyzing serum samples, the study aims to identify biomarkers that predict treatment response and survival outcomes. The researchers hypothesize that high levels of IL-6 and acute phase reactants are linked to poor responses to treatment, and they plan to combine IL-6 receptor blockade with existing therapies to enhance effectiveness and reduce side effects. This approach could lead to more personalized treatment strategies for patients with metastatic melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic melanoma who are receiving or have received immune checkpoint inhibitors.
Not a fit: Patients with melanoma who are not receiving immune checkpoint inhibitors or those with early-stage melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes and survival rates for melanoma patients by identifying effective combination therapies.
How similar studies have performed: Previous research has shown that targeting IL-6 can enhance the effectiveness of cancer therapies, suggesting a promising avenue for this approach.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Mehnert, Janice M. — New York University School of Medicine
- Study coordinator: Mehnert, Janice M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.